SCHEMBL1880854

SCHEMBL1880854

COc1cc(C=O)ccc1Oc1ccc2[nH]cnc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.54
▸ ALDH1A1 P00352 10/20 0.50
▸ TSHR P16473 1/20 0.50
▸ MAPT P10636 8/20 0.48
▸ FDPS P14324 1/20 0.48
▸ TDP1 Q9NUW8 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ MMP12 P39900 1/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HTT P42858 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ ATM Q13315 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ AOX1 Q06278 1/20 0.40
▸ TRIM24 O15164 1/20 0.40
▸ ALDH5A1 P51649 1/20 0.40
▸ ABAT P80404 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633819 0.90 MMP12 (0.56) TTRALDH1A1TSHRMAPTFDPS
SCHEMBL1874507 0.84 P2RY14 (0.42) TTRALDH1A1MAPTTDP1POLB
SCHEMBL1876553 0.82 P2RY14 (0.48) ALDH1A1MAPTTDP1POLBMMP12
SCHEMBL1877877 0.78 MMP12 (0.43) ALDH1A1POLBMMP12QPCTKDM4E
SCHEMBL17955067 0.77 TTR (0.81) TTRALDH1A1TSHRMAPTFDPS
SCHEMBL1160196 0.77 CYP2A6 (0.47) ALDH1A1MAPTTDP1MMP12KDM4E
SCHEMBL29505633 0.77 CYP2A6 (0.47) ALDH1A1MAPTTDP1MMP12KDM4E
SCHEMBL26936583 0.75 TTR (0.79) TTRALDH1A1TSHRMAPTFDPS
SCHEMBL12633845 0.75 P2RY14 (0.48) TTRALDH1A1MAPTTDP1POLB
SCHEMBL225931 0.73 MMP12 (0.73) ALDH1A1TSHRMAPTTDP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939528-B2 Heterocycle compounds GLAXOSMITHKLINE LLC (US) 2011-05-10 — — US disclosed
US-20090054431-A1 NOVEL HETEROCYCLE COMPOUNDS GLAXOSMITHKLINE LLC 2009-02-26 — — US disclosed
EP-1943226-A2 PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-16 — — EP disclosed
WO-2007047397-A2 PHENOL ETHERS AS MODULATORS OF THE OPIOID RECEPTORS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054431-A1 NOVEL HETEROCYCLE COMPOUNDS OPRK1, OPRL1, OPRD1 TTR 4804/4885ALDH1A1 1161/4885TSHR 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback